Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest CardioDx Inc. Stories

2013-11-25 08:27:45

- Corus® CAD Gene Expression Test Impacts Clinical Decision-Making in Primary Care Practices and Reduces Unnecessary Referrals for Cardiac Testing in this Special Population - PALO ALTO, Calif., Nov. 25, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced results from a multi-center, real-world registry study highlighting the clinical utility of Corus(®) CAD in evaluating suspected obstructive coronary artery...

2013-11-18 12:30:17

- Data Presented Demonstrate the Advantages of Corus® CAD in Improving Clinical Decision-Making and Reducing Diagnostic Test Overutilization in Women with Symptoms Suggestive of Obstructive Coronary Artery Disease - PALO ALTO, Calif., Nov. 18, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results from two studies reinforcing the value of Corus(®) CAD as an initial diagnostic test for the evaluation of...

2013-10-21 08:29:25

- Corus® CAD is Effective in Excluding the Diagnosis of Obstructive Coronary Artery Disease in the Primary Care Setting and Helps Reduce Unnecessary Healthcare Expense - PALO ALTO, Calif., Oct. 21, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of a multi-center, real-world registry study demonstrating the clinical utility of Corus® CAD, a blood-based gene expression test, in the evaluation of...

2013-10-11 16:24:01

PALO ALTO, Calif., Oct. 11, 2013 /PRNewswire/ -- CardioDx, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by CardioDx. The number of shares to be offered and the price range for the offering have not yet been determined. CardioDx has applied for a listing of its common stock on...

2013-10-10 08:29:32

- Corus® CAD Has Potential to Reduce Cardiac Diagnostic Costs in Women by More Than $500 per Patient - PALO ALTO, Calif., Oct. 10, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of two studies indicating that Corus(®) CAD, a blood-based gene expression test, may help reduce unnecessary cardiac testing and costs by aiding clinician decision-making in the evaluation of women with symptoms...

2013-09-03 08:28:48

Corus CAD Gene Expression Test Helped Cardiologists Determine Which Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease (CAD) Did Not Require Further Cardiac Testing PALO ALTO, Calif., Sept. 3, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of results from the Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern...

2013-08-26 16:23:34

- Sex-Specific Blood-based Genomic Test Helps Exclude the Diagnosis of Obstructive CAD in Symptomatic Patients - PALO ALTO, Calif., Aug. 26, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of a comprehensive review of the evidence demonstrating that Corus(®) CAD, a blood-based gene expression test, can help clinicians accurately and safely exclude obstructive coronary artery disease (CAD)...

2013-07-18 08:29:50

- Two Studies to be Presented at "What a Difference an X Makes: The State of Women's Health Research" Validate the Accuracy and Clinical Utility of Corus® CAD, the Only Sex-Specific Test for the Assessment of Obstructive Coronary Artery Disease - PALO ALTO, Calif., July 18, 2013 /PRNewswire/ -- CardioDx, Inc., a leader in the field of cardiovascular genomic diagnostics, today announced that the company will present two studies demonstrating the accuracy and clinical utility of...

2013-05-30 08:29:57

PALO ALTO, Calif., May 30, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the Jefferies 2013 Global Healthcare Conference, taking place June 3-6, 2013 in New York, NY. David Levison, the company's President and Chief Executive Officer, will provide an overview of CardioDx and Corus(®) CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD) on...

2013-05-20 08:27:53

- Use of Corus® CAD Led to a Statistically Significant Reduction in Additional Cardiac Testing - PALO ALTO, Calif., May 20, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the publication of the IMPACT-CARD (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) trial in Critical Pathways in Cardiology. This prospective study conducted at Vanderbilt University...